Cleared Traditional

NeutrArt (K201872) - FDA 510(k) Clearance

Class II General Hospital device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K201872 · Asset Medikal Tasarim As. · General Hospital
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jan 2021
Decision
182d
Days
Class 2
Risk

K201872 is an FDA 510(k) clearance for the NeutrArt. Classified as Set, Administration, Intravascular (product code FPA), Class II - Special Controls.

Submitted by Asset Medikal Tasarim As. (Istanbul, TR). The FDA issued a Cleared decision on January 5, 2021 after a review of 182 days - an extended review cycle.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.5440 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the General Hospital review framework, consistent with the majority of Class II 510(k) submissions.

View all Asset Medikal Tasarim As. devices

Submission Details

510(k) Number K201872 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 07, 2020
Decision Date January 05, 2021
Days to Decision 182 days
Submission Type Traditional
Review Panel General Hospital (HO)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
53d slower than avg
Panel avg: 129d · This submission: 182d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code FPA Set, Administration, Intravascular
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 880.5440
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General Hospital devices follow this clearance model.

Regulatory Consultant

Licensale, Inc.
Raymond Kelly

The regulatory consultant manages the 510(k) submission process on behalf of the applicant - coordinating technical documentation, predicate strategy and FDA communications. Identifying the consultant behind a submission is a key signal for competitive regulatory intelligence.

Regulatory Peers - FPA Set, Administration, Intravascular

All 238
Devices cleared under the same product code (FPA) and FDA review panel - the closest regulatory comparables to K201872.
Safety Subcutaneous Infusion Set
K201626 · Epic Medical Pte. , Ltd. · Mar 2021
Velano ExT Extension Set
K200439 · Velano Vascular · Feb 2021
Precision Delivery Infusion Set
K202672 · Quest Medical, Inc. · Jan 2021
Female Luer Lock Cap
K200425 · Medsafety Solutions, LLC · Oct 2020
MaxZero Extension Sets with Needle-Free Connector(s)
K193088 · Carefusion, Inc. · Oct 2020
Steripath Micro Blood Collection System
K200661 · Magnolia Medical Technologies, Inc. · Oct 2020